Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection
Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection
复制标题
DOI：
10.1016/j.vaccine.2012.09.003
复制
发表时间：
2012-11-06
期刊：
影响因子：
5.5
通讯作者：
He, Qiushui
中科院分区：
文献类型：
--
作者：
Barkoff, Alex-Mikael;Grondahl-Yli-Hannuksela, Kirsi;He, Qiushui
背景：百日咳毒素（PT）是百日咳博德特氏菌的特异性毒力因子，所有无细胞百日咳疫苗（aP）均含有该毒素。尽管感染后的免疫力似乎比接种疫苗后的免疫力持续时间更长，但确切的机制尚不清楚。本研究的主要目的是开发一种 ELISA 方法，用于测量 IgG-抗-PT 抗体的亲合力指数 (AI)，并比较加强疫苗接种和感染后的抗体反应。次要目的是评估 AI-ELISA 在百日咳血清诊断中是否具有潜力。材料：该研究纳入了总共 409 名受试者的血清样本。配对血清取自 97 名十年前接受加强疫苗 (dTpa-004) 的青少年和 80 名在上一次加强疫苗十年后接受第二剂加强疫苗 (dTpa-040) 的年轻人。包括来自培养证实的百日咳患者的 32 份配对血清、来自血清学诊断患者的 161 份单份血清和来自健康对照的 39 份单份血清。 IgG-抗-PT 抗体的 AI 通过新开发的 ELISA 测定，使用二乙胺 (DEA) 作为断键剂。通过标准化 ELISA 测量 IgG-抗-PT 抗体。 结果：十年前接种疫苗前和接种后一个月之间，发现抗体浓度和 AI 显着增加 [抗体 GMC：7.9 IU/ml vs. 98.3 IU/ml (p = 0.0001)； AI：40.4% vs. 56.1% (p= 0.0001)]。在第二次加强剂量后观察到类似的结果[抗体 GMC：9.2 IU/ml vs. 92.4 IU/ml (p = 0.0001)； AI：36.1% vs. 59.5% (p= 0.0001)]以及培养确诊患者的第一和第二份血清之间的差异[抗体的 GMC：6.9 IU/ml vs. 285.1 IU/ml (p= 0.0001)； AI：40.5% vs. 68.4% (p = 0.0001)]。健康对照者的抗体和 AI 水平均较低。结论：我们的结果表明，接种疫苗后和感染后，PT 抗体的质量和数量可能存在差异。此外，人工智能可以为疫苗研究提供帮助。 (C) 2012 Elsevier Ltd. 保留所有权利。
Background: Pertussis toxin (PT) is a specific virulence factor of Bordetella pertussis and it is included in all acellular pertussis vaccines (aP). Although immunity after infection seems to persist longer than that after vaccination, the exact mechanism(s) is not known. Primary aim of this study was to develop an ELISA method for measuring avidity index (AI) of IgG-anti-PT antibodies and to compare antibody responses after booster vaccination and infection. Secondary aim was to evaluate if the AI-ELISA has potential in the serodiagnosis of pertussis.Material: Serum samples from a total of 409 subjects were included in the study. Paired sera were taken from 97 adolescents who received booster vaccine ten years ago (dTpa-004) and from 80 young adults who received a second booster dose ten years after the previous booster vaccine (dTpa-040). Thirty-two paired sera from culture-confirmed pertussis patients, 161 single sera from serologically diagnosed patients and 39 single sera from healthy controls were included. AI of IgG-anti-PT antibodies were determined with newly developed ELISA using diethylamine (DEA) as a bond breaking agent. The IgG-anti-PT antibodies were measured by standardized ELISA.Results: A significant increase was found in antibody concentrations and AI between PRE and one month POST vaccination ten years ago [GMC for antibody: 7.9 IU/ml vs. 98.3 IU/ml (p = 0.0001); for AI: 40.4% vs. 56.1% (p= 0.0001)]. Similar result was observed after the second booster dose [GMC for antibody: 9.2 IU/ml vs. 92.4 IU/ml (p = 0.0001); for AI: 36.1% vs. 59.5% (p= 0.0001)] and between the first and second sera of culture-confirmed patients [GMC for antibody: 6.9 IU/ml vs. 285.1 IU/ml (p= 0.0001); for AI: 40.5% vs. 68.4% (p = 0.0001)]. Healthy controls showed lower levels of both antibodies and AI.Conclusions: Our results suggest that there may be difference in quality and quantity of antibodies to PT after vaccination and after infection. Furthermore, AI could be a help for vaccine studies. (C) 2012 Elsevier Ltd. All rights reserved.